CDT Equity Inc.
CDTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$36.8M | −$15.4M | −$5.3M | −$3.2M | −$4,381 |
| Net income | −$39.2M | −$17.8M | −$535,000 | −$4.9M | −$4,381 |
| Total assets | $5.7M | $4.2M | $7.2M | $5,000 | $213,125 |
| Total liabilities | $12.8M | $11.0M | $7.7M | $10.1M | $192,506 |
| Equity | −$7.2M | −$6.8M | −$457,000 | −$10.1M | −$6.0M |
| EPS (diluted) | $-1177.89 | $-20.53 | $-8.92 | $-0.13 | — |
| Shares out. | 6.7M | 73.8M | 738,295 | 14.0M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 547.1%
- Return on assets
- −694.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 226.9%
- Debt / equity
- —
- Book value / share
- $-1.08
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -93.53distress
- Accruals / assets
- −418.9%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Nirland LtdPassive (13G)May 20, 2026
- Corvus Capital Ltd.Activist (13D)May 14, 2026
- Taylor Mark AndrewActivist (13D)Mar 30, 2026
- Ascent Partners Fund LlcPassive (13G)Feb 18, 2026
- Sarborg LtdPassive (13G)Aug 18, 2025
- A.G.P. / Alliance Global Partners, LlcPassive (13G)May 15, 2025
- Astrazeneca PlcPassive (13G)Apr 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 31,350 | 1.0 | +7.0% |
| Apr 30, 2026 | 29,314 | 1.0 | +41.6% |
| Apr 15, 2026 | 20,708 | 1.0 | -77.6% |
| Mar 31, 2026 | 92,355 | 1.0 | -28.9% |
| Mar 13, 2026 | 129,934 | 1.2 | -26.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Regulation FD disclosureMay 28, 2026
- Entered a material agreementMay 15, 2026
- Director / officer changeApr 27, 2026
- Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureMar 25, 2026
- Shareholder voteMar 18, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleMar 9, 2026
- Entered a material agreement · Unregistered equity saleFeb 24, 2026
- Entered a material agreement · Unregistered equity saleJan 22, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.